The Novel Targeted Therapy for Glaucoma, co-developed with TheratOcular Biotek, is a dual-target eye drop that significantly improves trabecular meshwork blockage and facilitates the drainage of aqueous humor to regulate intraocular pressure (IOP). This dual-target drug overcomes prevailing limitations of side effects and surpasses existing medications with three times the efficacy in reducing IOP. In addition to its efficacy in treating glaucoma, it is suitable for individuals with elevated intraocular pressure.